Share:
JACKSONVILLE, Fla., Dec. 12, 2020 (GLOBE NEWSWIRE) The National Lipid Association (NLA) today announced the release of its official scientific statement on coronary artery calcium (CAC) scoring for atherosclerotic cardiovascular disease (ASCVD) risk reduction. The statement provides updates on the evidence-based appropriate use of CAC scoring and makes practical recommendations to aid clinicians in primary prevention treatment decision-making in contemporary clinical practice. Coronary calcium scoring is the best available non-invasive marker of cardiovascular risk, Stated the corresponding author, Carl E. Orringer, MD, Associate Professor Medicine at the University of Miami, Miller School of Medicine, Cardiovascular Division. This manuscript addresses the key questions that clinicians have about this test and provides up-to-date, evidence-based recommendations for optimal use of this technology for cardiovascular disease prevention.
New collaborative study to address key questions about COVID-19
A new nationwide study of more than 50,000 individuals is underway to determine factors that predict disease severity and long-term health impacts of COVID-19.
Researchers at the University of Colorado Anschutz Medical Campus are part of the NIH-funded study, the Collaborative Cohort of Cohorts for COVID-19 Research (C4R) Study, which includes 37 academic medical centers across the country. Participants in C4R are currently enrolled in 14 long-term studies at cohort institutions.
The new collaborative study will be able to answer important questions about COVID-19 that cannot be answered by smaller, individual studies that have been set up to study COVID-19.